GlaxoSmithKline's immunology leader Nucala has been locked in a yearslong struggle with AstraZeneca's Fasenra for dominance in rare eosinophilic asthma. With a new rare disease approval, Nucala just ...

AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with polyangiitis (EGPA) as the US Food and Drug Administration (FDA) approved the ...

GlaxoSmithKline’s Nucala needs a win in its fight against AstraZeneca’s Fasenra. Now, it can at least tout a first-data advantage in a rare inflammatory disease. In a phase 3 study, the rate of ...

The FDA has approved Nucala (mepolizumab; GlaxoSmithKline) for injection as add-on maintenance treatment of patients with severe asthma aged ≥12 years. The Food and Drug Administration (FDA) has ...

GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

Japan's Ministry of Health, Labour and Welfare (MHLW) has approved for GSK’s Nucala (mepolizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) whose condition is ...

GlaxoSmithKline announced the launch of Nucala (mepolizumab) for the treatment of patients aged ≥12 years with severe asthma with an eosinophilic phenotype. GlaxoSmithKline announced the launch of ...

The study is the first prospective global real-world study of a biologic treatment in patients with severe eosinophilic asthma. GlaxoSmithKline has presented new data for Nucala (mepolizumab) from an ...

GlaxoSmithKline’s Nucala has been approved for use in paediatric patients with severe eosinophilic asthma. GlaxoSmithKline’s Nucala has been approved for use in paediatric patients with severe ...